Citi raised the firm’s price target on Roivant Sciences (ROIV) to $42 from $35 and keeps a Buy rating on the shares. The firm sees further share upside on Roivant’s second half of 2026 data catalysts. The stock remains a top pick at Citi following the IMVT-1402 data.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV: